TABLE II.
Characteristic | Follow-up | p Valuea | |||
---|---|---|---|---|---|
| |||||
5 Years | At end | ||||
|
|
||||
CIF | 95% CI | CIF | 95% CI | ||
Race | <0.001 | ||||
White | 7.27 | 6.98 to 7.49 | 8.63 | 8.15 to 9.06 | |
Asian American | 12.25 | 11.57 to 13.14 | 14.02 | 13.26 to 14.75 | |
| |||||
Age group at diagnosis | <0.001 | ||||
<25 Years | 0.46 | 0.31 to 0.60 | 0.60 | 0.43 to 0.76 | |
25–45 Years | 3.41 | 3.22 to 3.60 | 4.24 | 4.02 to 4.45 | |
45–60 Years | 18.23 | 17.37 to 19.09 | 21.89 | 20.93 to 22.86 | |
>60 Years | 31.29 | 30.04 to 32.54 | 36.07 | 34.73 to 37.40 | |
| |||||
FIGO stage (1994) | <0.001 | ||||
In situ | 0.40 | 0.34 to 0.46 | 0.86 | 0.76 to 0.95 | |
I | 9.56 | 8.99 to 10.14 | 13.11 | 12.38 to 13.85 | |
II | 39.16 | 37.32 to 41.01 | 47.85 | 45.67 to 50.03 | |
III | 60.42 | 58.09 to 62.74 | 67.86 | 65.27 to 70.45 | |
IV | 81.85 | 79.39 to 84.32 | 84.76 | 82.38 to 87.14 | |
| |||||
Lymph node metastasis | <0.001 | ||||
None | 3.24 | 3.08 to 3.39 | 4.22 | 4.04 to 4.40 | |
Regional | 45.66 | 43.31 to 48.02 | 53.36 | 50.71 to 56.01 | |
Distant | 78.33 | 74.68 to 81.98 | 80.95 | 77.46 to 84.45 | |
| |||||
Registry area | <0.001 | ||||
Middle | 7.87 | 7.49 to 8.25 | 9.09 | 8.68 to 9.49 | |
Eastern | 7.96 | 7.54 to 8.38 | 9.71 | 9.24 to 10.19 | |
Western | 7.07 | 6.72 to 7.41 | 8.33 | 7.95 to 8.71 | |
| |||||
Marital status | <0.001 | ||||
Single or other | 5.41 | 5.03 to 5.79 | 6.14 | 5.74 to 6.55 | |
Married | 9.87 | 9.56 to 10.19 | 11.70 | 11.36 to 12.05 | |
| |||||
Primary site | <0.001 | ||||
Endocervix | 12.08 | 11.12 to 13.05 | 15.18 | 14.08 to 16.29 | |
Exocervix | 3.16 | 2.53 to 3.78 | 4.60 | 3.79 to 5.40 | |
Overlapping lesion | 3.76 | 2.82 to 4.70 | 5.33 | 4.20 to 6.48 | |
Cervix uteri | 7.59 | 7.35 to 7.83 | 8.82 | 8.57 to 9.09 | |
| |||||
Grade | <0.001 | ||||
Undifferentiated | 10.27 | 8.77 to 11.76 | 14.06 | 12.12 to 16.01 | |
Poorly differentiated | 24.92 | 23.64 to 26.21 | 30.51 | 28.95 to 32.06 | |
Moderately differentiated | 36.28 | 35.07 to 37.90 | 41.74 | 40.18 to 43.30 | |
Well differentiated | 40.81 | 36.35 to 45.27 | 42.73 | 38.19 to 47.27 | |
| |||||
Histology | <0.001 | ||||
Squamous cell | 7.65 | 7.38 to 7.92 | 9.07 | 8.77 to 9.37 | |
Adenocarcinoma | 17.63 | 16.46 to 18.79 | 21.79 | 20.45 to 23.13 | |
Adenosquamous | 31.22 | 27.88 to 34.57 | 35.23 | 31.68 to 38.77 | |
Others | 3.29 | 3.00 to 3.59 | 3.92 | 3.60 to 4.24 | |
| |||||
Tumour diameter | <0.001 | ||||
<7 mm | 0.50 | 0.35 to 0.65 | 1.05 | 0.81 to 1.28 | |
7 mm–4 cm | 18.45 | 17.12 to 19.78 | 24.21 | 22.52 to 25.89 | |
>4 cm | 46.04 | 44.21 to 478.87 | 52.78 | 50.68 to 54.88 | |
| |||||
Radiation | <0.001 | ||||
Yes | 41.53 | 40.43 to 42.63 | 49.31 | 48.06 to 50.57 | |
No | 2.01 | 1.89 to 2.14 | 2.73 | 2.58 to 2.88 | |
| |||||
Surgery | <0.001 | ||||
Yes | 2.96 | 2.81 to 3.12 | 4.00 | 3.82 to 4.19 | |
No | 29.99 | 29.07 to 30.90 | 33.23 | 32.27 to 34.19 |
By the Gray test.
CIF = cumulative incidence function; CI = confidence interval; FIGO = Fédération Internationale de Gynécologie et d’Obstétrique.